company background image
TWST

Twist BioscienceNasdaqGS:TWST Stock Report

Market Cap

US$5.8b

7D

4.1%

1Y

36.6%

Updated

24 Oct, 2021

Data

Company Financials +
TWST fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

TWST Overview

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.

Twist Bioscience Competitors

CureVac

NasdaqGM:CVAC

US$7.5b

Thermo Fisher Scientific

NYSE:TMO

US$240.8b

Danaher

NYSE:DHR

US$223.9b

Illumina

NasdaqGS:ILMN

US$64.0b

Price History & Performance

Summary of all time highs, changes and price drops for Twist Bioscience
Historical stock prices
Current Share PriceUS$117.41
52 Week HighUS$74.25
52 Week LowUS$214.07
Beta0.75
1 Month Change4.73%
3 Month Change2.10%
1 Year Change36.57%
3 Year Changen/a
5 Year Changen/a
Change since IPO738.64%

Recent News & Updates

Oct 05

Twist Stock: Manufacturing The Future

Twist Bioscience is a synthetic biology company that is able to produce DNA at significantly lower costs than competitors. There is uncertainty as to whether Twist’s technological advantage is sustainable or if a more productive technology will be developed. Next-Generation Sequencing revenue growth is strong and is likely to remain so as costs continue to decline and applications like liquid biopsy are commercialized. Revenue from drug discovery and data storage is uncertain but could provide significant upside. Twist's stock is relatively expensive but this reflects the size of their opportunity.

Sep 21
Is Twist Bioscience (NASDAQ:TWST) Using Too Much Debt?

Is Twist Bioscience (NASDAQ:TWST) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

TWSTUS BiotechsUS Market
7D4.1%0.5%1.7%
1Y36.6%16.1%30.3%

Return vs Industry: TWST exceeded the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: TWST exceeded the US Market which returned 30.3% over the past year.

Price Volatility

Is TWST's price volatile compared to industry and market?
TWST volatility
TWST Beta0.75
Industry Beta0.98
Market Beta1

Stable Share Price: TWST is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: TWST's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013525Emily Leprousthttps://www.twistbioscience.com

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Twist Bioscience Fundamentals Summary

How do Twist Bioscience's earnings and revenue compare to its market cap?
TWST fundamental statistics
Market CapUS$5.79b
Earnings (TTM)-US$135.17m
Revenue (TTM)US$126.81m

45.6x

P/S Ratio

-42.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TWST income statement (TTM)
RevenueUS$126.81m
Cost of RevenueUS$75.70m
Gross ProfitUS$51.11m
ExpensesUS$186.29m
Earnings-US$135.17m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.74
Gross Margin40.31%
Net Profit Margin-106.59%
Debt/Equity Ratio0.4%

How did TWST perform over the long term?

See historical performance and comparison

Valuation

Is Twist Bioscience undervalued compared to its fair value and its price relative to the market?

9.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TWST's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TWST's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TWST is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: TWST is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TWST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TWST is overvalued based on its PB Ratio (9.5x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Twist Bioscience forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-6.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TWST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TWST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TWST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TWST's revenue (22.3% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: TWST's revenue (22.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TWST is forecast to be unprofitable in 3 years.


Past Performance

How has Twist Bioscience performed over the past 5 years?

-22.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TWST is currently unprofitable.

Growing Profit Margin: TWST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TWST is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.

Accelerating Growth: Unable to compare TWST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TWST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: TWST has a negative Return on Equity (-22.14%), as it is currently unprofitable.


Financial Health

How is Twist Bioscience's financial position?


Financial Position Analysis

Short Term Liabilities: TWST's short term assets ($576.6M) exceed its short term liabilities ($54.8M).

Long Term Liabilities: TWST's short term assets ($576.6M) exceed its long term liabilities ($60.0M).


Debt to Equity History and Analysis

Debt Level: TWST's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TWST's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TWST has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TWST has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.1% each year


Dividend

What is Twist Bioscience current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TWST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TWST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TWST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TWST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TWST's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Emily Leproust (48 yo)

8.5yrs

Tenure

US$7,436,572

Compensation

Dr. Emily Marine Leproust, Ph D., serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She serves as an Independent Director at Sema4 Holdings Corp. (formerly known as Mount Si...


CEO Compensation Analysis

Compensation vs Market: Emily's total compensation ($USD7.44M) is about average for companies of similar size in the US market ($USD6.33M).

Compensation vs Earnings: Emily's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: TWST's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: TWST's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TWST insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.4%.


Top Shareholders

Company Information

Twist Bioscience Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Twist Bioscience Corporation
  • Ticker: TWST
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.787b
  • Shares outstanding: 49.29m
  • Website: https://www.twistbioscience.com

Number of Employees


Location

  • Twist Bioscience Corporation
  • 681 Gateway Boulevard
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/24 22:26
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.